Free Newsletter
Biggest Battles in Biopharma
You know the picture: Two pharma CEOs, shaking hands and smiling as cameras flash and video rolls. It's been common enough, especially recently, as Pfizer and Wyeth, Merck and Schering-Plough announced their big mergers.
But that's not always the way M&A goes. While many pharma deals over the past 20 years have been relatively friendly, others haven't. Hostile bids, media grandstanding, warring press releases--unfriendly mergers have triggered them all.
The following list includes some of the biggest battles of the last two decades. We've covered a few of them ourselves, but others are before our time, such as Pfizer's Warner-Lambert takeover. Click below to get all the details on some of the industry's biggest takeover battles.
Click here to get started ![]()
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: